Yu Hu

Yu Hu

Auto-generated profile, based on publicly available information

Yu Hu

Department of Physiotherapy, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College , Nanjing

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
YCYan Chen
Yan Chen
JXJianfeng Xie
Jianfeng Xie
WWWenjuan Wu
Wenjuan Wu
SLShusheng Li
Shusheng Li
YHYu Hu
Yu Hu
BDBin Du
Bin Du
Background: The benefits of intravenous immunoglobulin administration are controversial for critically ill COVID-19 patients.Methods: We analyzed retrospectively the effects of immunoglobulin administration for critically ill COVID-19 patients. The primary outcome was 28-day mortality. Inverse probability of treatment weighting (IPTW) with propensity score was used to account for baseline confounders. Cluster analysis was used to perform phenotype analysis.Results: Between January 1 and February 29, 2020, 754 patients with complete data from 19 hospitals were enrolled. Death at 28 days occurred for 408 (54.1%) patients. There were 392 (52.0%) patients who received intravenous immunoglobulin, at 11 (interquartile range (IQR) 8, 16) days after illness onset; 30% of these patients received intravenous immunoglobulin prior to intensive care unit (ICU) admission. By unadjusted analysis, no difference was observed for 28-day mortality between the immunoglobulin and non-immunoglobulin groups. Similar results were found by propensity score matching (n = 506) and by IPTW analysis (n = 731). Also, IPTW analysis did not reveal any significant difference between hyperinflammation and hypoinflammation phenotypes.Conclusion: No significant association was observed for use of intravenous immunoglobulin and decreased mortality of severe COVID-19 patients. Phenotype analysis did not show any survival benefit for patients who received immunoglobulin therapy.

3 October 2022 in Dermatologic Therapy
Verified
Journal Article
Closed access
RLRong Li
Rong Li
YHYu Hu
Yu Hu
MWMin‐Zhi Wu
Min‐Zhi Wu
KCKun Chen
Kun Chen

6 July 2022 in Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Verified
Journal Article
Closed access
YHY L Hu
Y L Hu
RYR J Yan
R J Yan
YJY Jiang
Y Jiang
JZJ W Zhang
J W Zhang
LYL L Ye
L L Ye
JZJuan Zhang
Juan Zhang
Objective: To investigate the preference for Front-of-Pack Labeling (FOP) and its association with the understanding of the Nutrition Facts Panel among Chinese residents. Methods: A multi-stage sampling strategy was adopted to select 3 002 people aged between 18 and 70 years old from the eastern region of China (Beijing, Jiangsu Province, Guangdong Province), the northeast region (Heilongjiang Province), the central region (Henan Province) and the western region (Sichuan Province) from July 2020 to March 2021. Socio-demographic characteristics of participants and their understanding of the Nutrition Facts Panel and preference for FOP were collected. The χ² test was conducted to compare the preference for FOP in different groups of population, and multivariate logistic regression was used to analyze the association between the preference for FOP and the understanding of the Nutrition Facts Panel. Results: The mean age of 3 002 participants was (42.3±13.4) years, of which 1 914 (63.8%) were females and 69.3% could not understand the Nutrition Facts Panel. About 2 458 respondents (81.9%) suggested that FOP could be promoted. The top three nutrients that should be labeled were sugar (68.4%), salt (68.2%) and total fat (62.4%). The number of participants who believed that the Multiple Traffic Lights (MTL) could be easier to help consumers to quickly choose healthy food, attract attention and provide the most needed information was 1 064 (35.4%), 1 026 (34.2%) and 1 140 (38.0%), respectively. The multivariate logistic regression analysis showed that, compared with the Guideline Daily Amount (GDA) system, participants who could not understand the Nutrition Facts Panel preferred (1) Nutri-Score, Warning labels, and Health logos: Smart Choice in terms of"Which format of FOP could quickly help you choose food more easily?"[OR (95%CI): 2.21 (1.62-3.02), 1.64 (1.22-2.22), 1.79 (1.31-2.45), respectively]; (2) Nutri-Score, Warning labels, and Health logos: Smart Choice in terms of"Which format of FOP could attract your attention the most?"[OR (95%CI): 2.62 (1.92-3.59), 1.96 (1.45-2.66), 2.25 (1.66-3.04), respectively]; and (3) Nutri-Score, Warning labels, and Health logos: Smart Choice in terms of"Which format of FOP could provide you with the most needed information?"[OR (95%CI): 2.33 (1.70-3.21), 2.21 (1.66-2.95), 2.01 (1.50-2.71), respectively]. Conclusion: The residents from six provinces in China have a supportive attitude towards FOP. The interpretive FOP with color information, specific nutrient information and summary indicator can be launched. The nutrition information of sugar, salt and total fat could be prioritized to be labeled on the FOP.

19 October 2019 in Trends in Immunotherapy
Verified
Journal Article
Open access
PDF file
YHYu Hu
Yu Hu
LLLin Lin
Lin Lin
PCPangen Cui
Pangen Cui
XYXu Yao
Xu Yao
CLChao Luan
Chao Luan
MCMin Chen
Min Chen
Severe psoriasis patients are reported to have a higher risk of liver abnormalities. Treatment option for severe psoriasis patients with liver disorder history remains a great challenge. Hepatic toxicity and long-term safety are the major concerns. Hence it is necessary to look for safer and more effective treatment for those patients. This retrospective review evaluated the safety and efficacy of combination therapy of infliximab and total glucosides of paeony (TGP) in treating 13 severe psoriasis patients with liver disorder history. Patients with severe psoriasis, comprising eight men and five women with a mean age of 37.3 ± 12.3, were observed. The patients experienced a mean course of psoriasis of 11.2 ± 7.1 years. The mean psoriasis area and severity index (PASI) score was 29.3 ± 12.9. All patients have the history of liver disorder. In our study, these patients were treated with infliximab at a dose of 5 mg/kg and TGP at a dose of 1.8 g/day. No liver test abnormalities were seen during combination therapy. After treatment, 61.5% patients showed PASI 50 response at week 2, and 81.8% patients have PASI 75 response at week 6. The mean time for achieving PASI 75 and PASI 90 improvement was 4.2 weeks and 9.6 weeks, respectively. Our observation demonstrates that combined therapy of infliximab and TGP is effective and safe in the treatment of severe psoriasis, especially for patients with liver disorder history.

8 February 2026 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
XDXiaoxi Dai
Xiaoxi Dai
YHYu Hu
Yu Hu
DHDan Huang
Dan Huang
ZXZhuohong Xu
Zhuohong Xu
LLLihao Liu
Lihao Liu
JZJiaan Zhang
Jiaan Zhang
Photoaging, a major form of extrinsic skin aging, primarily results from chronic ultraviolet (UV) irradiation. Although accumulating evidence implicates transfer RNA-derived small RNAs (tsRNAs) in aging, inflammation and oxidative stress, their precise roles in photoaging remain insufficiently defined. To investigate the function of tRNA-derived fragment (tRF)-34 in photoaging and to define the underlying molecular mechanism. tRF-34 expression was evaluated in UVA1-irradiated primary human dermal fibroblasts (HDFs), murine skin, and sun-exposed human skin using RT-qPCR and fluorescence in situ hybridization. Functional characterization was performed with tRF-34 overexpression and knockdown. Downstream mechanisms were elucidated mainly using RNA sequencing, RNA pull-down, RNA immunoprecipitation and m⁶A methylation analysis. tRF-34 was significantly downregulated in photoaged HDFs. Restoration of tRF-34 ameliorated photoaging in HDFs, while its inhibition exacerbated senescence-related features. Mechanistically, tRF-34 bound to YTHDF2, inhibiting YTHDF2-mediated m⁶A-dependent degradation of natriuretic peptide receptor C (NPRC) mRNA. NPRC, also diminished in photoaging, exerted photoprotective effects through activation of TGF-β1/Smad signaling. In vivo, tRF-34 overexpression mitigated chronic UVA1-induced wrinkle formation and improved collagen content in photoaged mice. Our work establishes a novel tRF-34/YTHDF2/NPRC regulatory axis that preserves skin homeostasis against chronic UV damage, providing new mechanistic insights and suggesting a potential basis for future translational exploration in photoaging.

23 June 2017 in Trends in Immunotherapy
Verified
Journal Article
Open access
YHYu Hu
Yu Hu
LLLin Lin
Lin Lin
PCPangen Cui
Pangen Cui
XYXu Yao
Xu Yao
CLChao Luan
Chao Luan
MCMin Chen
Min Chen
Severe psoriasis patients are reported to have a higher risk of liver abnormalities. Treatment option for severe psoriasis patients with liver disorder history remains a great challenge. Hepatic toxicity and long-term safety are the major concerns. Hence it is necessary to look for safer and more effective treatment for those patients. This retrospective review evaluated safety and efficacy of combination therapy of infliximab and TGP in treating 13 severe psoriasis patients with liver disorder history.Thirteen patients with severe psoriasis, including 8 men and 5 women, with a mean age of 37.3 ± 12.3 were observed. The patients experienced a mean course of psoriasis of 11.2 ± 7.1 years. The mean PASI score was 29.3 ± 12.9. All patients have the history of liver disorder. In our study, these patients were treated with infliximab at a dose of 5mg/kg and TGP at a dose of 1.8g/day. No liver test abnormalities were seen during combination therapy. After treatment, 61.5% patients showed PASI 50 response at week 2, and 81.8% patients have PASI 75 response at week 6. The mean time for achieving PASI 75 and PASI 90 improvement was 4.2 week and 9.6 week, respectively. Conclusion: Our observation demonstrates that combined therapy of infliximab and TGP is effective and safe in the treatment of severe psoriasis, especially for the patients with liver disorder history.